Drugs / TAK-781
last change Jan 2026 re-read 3 minutes ago

TAK-781

Developed for
primary sclerosing cholangitis
Investigated by
Takeda

Trials 1

202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07229911 Jan 2026 → Apr 2028 expected primary sclerosing cholangitis Takeda Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TAK-781 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07229911 ↗